Evidence map›Paper›PMID 35868584›Full record

ArticleJournal of hepatology2022

Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.

Thomas Marjot, Christiane S Eberhardt, Tobias Boettler, Luca S Belli, Marina Berenguer, Maria Buti, Rajiv Jalan, Mario U Mondelli, Richard Moreau, Daniel Shouval and 2 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Observational
  11. Review
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Thomas MarjotOxford Liver Unit, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK; Nuffield Department of Medicine, Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
Christiane S EberhardtCenter for Vaccinology and Neonatal Immunology, Department of Pathology and Immunology, University of Geneva, Switzerland; Division of General Pediatrics, Department of Woman, Child and Adolescent Medicine, Faculty of Medicine, University of Geneva, Center for Vaccinology, Geneva University Hospitals, Geneva, Switzerland.
Tobias BoettlerDepartment of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Luca S BelliDepartment of Hepatology and Gastroenterology, GOM Niguarda, Milan, Italy.
Marina BerenguerLiver Transplantation and Hepatology Unit and Ciberehd, IISLaFe and Hospital Universitario y Politécnico La Fe, Valencia, Spain; Department of Medicine, Universitat de València, Valencia, Spain.
Maria ButiLiver Unit, Hospital Universitario Valle Hebron, Barcelona, and CIBEREHD del Instituto Carlos II, Spain.
Rajiv JalanLiver Failure Group, Institute for Liver and Digestive Health, University College London, Royal Free Campus, London and European Foundation for the Study of Chronic Liver Failure, Barcelona.
Mario U MondelliDivision of Clinical Immunology and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo and Department of Internal Medicine and Therapeutics, University of Pavia, Italy.
Richard MoreauEuropean Foundation for the Study of Chronic Liver Failure, Barcelona, Spain; Service d'Hépatologie, Hôpital Beaujon, APHP, Clichy, France; Centre de Recherche sur l'Inflammation, INSERM and Université de Paris Cité, Paris, France.
Daniel ShouvalLiver Unit, Hadassah-Hebrew University Hospital, Jerusalem, Israel.
Thomas BergDivision of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.
Markus CornbergCentre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz Centre for Infection Research (HZI) and Hannover Medical School (MHH), Hannover, Germany; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School (MHH), Hannover, Germany; German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Germany. Electronic address: cornberg.markus@mh-hannover.de.

Funding

Wellcome Trust 102176/B/13/Z
6 · The paper itself

Abstract

The COVID-19 pandemic has presented a serious challenge to the hepatology community, particularly healthcare professionals and patients. While the rapid development of safe and effective vaccines and treatments has improved the clinical landscape, the emergence of the omicron variant has presented new challenges. Thus, it is timely that the European Association for the Study of the Liver provides a summary of the latest data on the impact of COVID-19 on the liver and issues guidance on the care of patients with chronic liver disease, hepatobiliary cancer, and previous liver transplantation, as the world continues to deal with the consequences of the COVID-19 pandemic.

Indexed as

COVID-19Liver DiseasesLiver TransplantationNeoplasmsHumansPandemicsSARS-CoV-2chronic liver diseasecirrhosisCOVID-19hepatobiliary cancerliver transplantationSARS-CoV-2vaccination

Identifiers

PMID35868584
PMCPMC9296253

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.